Side-by-side comparison of AI visibility scores, market position, and capabilities
Dutch health technology company with €17B revenue; MRI/CT imaging and patient monitoring managing massive sleep apnea device recall competing with Siemens Healthineers and GE HealthCare.
Philips is a Dutch multinational technology and health technology company that has transformed from a broad consumer electronics conglomerate into a focused health technology leader — producing diagnostic imaging systems (MRI, CT, ultrasound), patient monitoring, hospital informatics, personal health products (electric toothbrushes, shavers, sleep apnea devices), and health informatics solutions. Listed on the Amsterdam Stock Exchange (AEX: PHIA) and headquartered in Amsterdam, Philips generates approximately €17 billion ($18 billion) in annual revenue after divesting its lighting division (now Signify) and domestic appliances business.\n\nPhilips' health technology portfolio spans two segments: Diagnosis & Treatment (imaging systems, image-guided therapy, and ultrasound for hospitals) and Connected Care (patient monitoring, respiratory care, sleep therapy). The Diagnosis & Treatment segment provides MRI systems, CT scanners, and X-ray equipment to hospitals globally. The Connected Care segment includes Philips' DreamStation and other sleep apnea (CPAP/BiPAP) devices, home respiratory care, and hospital patient monitoring platforms.\n\nIn 2025, Philips is managing the severe consequences of a 2021 recall of approximately 5.5 million sleep apnea devices (Philips Respironics DreamStation and related models) due to concerns that degraded polyester foam could release harmful particles and gases — one of the largest medical device recalls in history. The recall has resulted in multi-billion dollar settlements, regulatory scrutiny, and significant reputation damage in the sleep therapy market, allowing competitors ResMed and Fisher & Paykel to gain share. Philips' 2025 strategy focuses on resolving recall liabilities, rebuilding the sleep therapy business, and investing in AI-powered diagnostic imaging to compete with Siemens Healthineers and GE HealthCare.
$3.5M annual revenue 2025; $86.1M total funding (Series C Oct 2023); deployed in 60+ countries; acquired Regen adding 130K acres; 134 employees; precision agriculture market $8.7B 2024; subscription-based model
CropX was founded in 2014 in Tel Aviv, Israel, with the mission of helping farmers improve crop yields and reduce resource consumption through precision agriculture technology. The company developed soil sensing hardware and analytics software that translate subsurface soil data into actionable irrigation and nutrient management recommendations, enabling farms of any size to optimize inputs based on actual field conditions rather than generalized agronomic guidelines.\n\nCropX's platform combines wireless soil sensors that measure moisture, temperature, and electrical conductivity at multiple depths with a cloud-based analytics engine that integrates weather data, satellite imagery, and farm management records. Recommendations are delivered via a mobile app, enabling farm managers to make data-driven irrigation decisions in real time. The 2023 acquisition of Regen added 130,000 acres of managed farmland to its platform and expanded its capabilities in carbon and regenerative agriculture. CropX is deployed in 60+ countries across a diverse range of crops and farm types.\n\nCropX has raised $86.1M in total funding, including a Series C in October 2023, and has grown to serve 20,000+ customers with a team of 134 employees. The company's international deployment footprint — spanning North America, Europe, Australia, and emerging agricultural markets — reflects the universal applicability of data-driven soil management. CropX sits at the intersection of precision agriculture, water conservation, and sustainable farming, three of the highest-priority investment themes in global food systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.